Secondary anchor substitutions in an HLA-A*0201-restricted T-cell epitope derived from Her-2/neu

Molecular Immunology

Volumn 44, Issue 4, 2007, Pages 322-331

  Joseph, Matthew A ^a   Mitchell, Megan L ^a   Evanseck, Jeffrey D ^a   Kovacs, Jeffrey R ^a   Jia, Liang ^a   Shen, Hongmei ^b   Meng, Wilson S ^a  

^a DUQUESNE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Altered peptide ligand; Her 2 neu; HLA A*0201; Molecular dynamics; Tumor vaccine

Indexed keywords

CANCER ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GLYCYLISOLEUCYLLEUCYLGLYCYLPHENYLALANYLVALYLPHENYLALANYLTHREONYLLEUCINE; HLA A ANTIGEN; ISOLEUCYLISOLEUCYLSERYLALANYLVALYLGLUTAMINYLGLYCYLISOLEUCYLLEUCINE; ISOLEUCYLISOLEUCYLSERYLALANYLVALYLGLUTAMINYLPHENYLALANYLISOLEUCYLLEUCINE; ISOLEUCYLISOLEUCYLSERYLALANYLVALYLSERYLGLYCYLISOLEUCYLLEUCINE; ISOLEUCYLISOLEUCYLSERYLALANYLVALYLTHREONYLGLYCYLISOLEUCYLLEUCINE; ISOLEUCYLISOLEUCYLSERYLALANYLVALYLTHREONYLPHENYLALANYLISOLEUCYLLEUCINE; ISOLEUCYLISOLEUCYLSERYLALANYLVALYLVALYLGLYCYLISOLEUCYLLEUCINE; ISOLEUCYLISOLEUCYLSERYLALANYLVALYLVALYLPHENYLALANYLISOLEUCYLLEUCINE; ISOLEUCYLISOLEUCYLSERYLALANYLVALYLVALYLPROLYLISOLEUCYLLEUCINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CONFORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG POTENCY; EPITOPE MAPPING; HLA SYSTEM; IMMUNIZATION; IMMUNOPHARMACOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STABILITY; PROTEIN STRUCTURE; RAT; SIMULATION; STRUCTURAL PROTEOMICS; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

AMINO ACID SUBSTITUTION; ANIMALS; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A ANTIGENS; MICE; MICE, TRANSGENIC; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

MUS MUSCULUS;

EID: 33747858421     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.02.027     Document Type: Article

References (44)

1. Abrams S.I., and Schlom J. Rational antigen modification as a strategy to upregulate or downregulate antigen recognition. Curr. Opin. Immunol. 12 (2000) 85-91
2. Bakker A.B., Schreurs M.W., Tafazzul G., de Boer A.J., Kawakami Y., Adema G.J., and Figdor C.G. Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line. Int. J. Cancer 62 (1995) 97-102
3. Baxevanis, C.N., Sotiriadou, N.N., Gritzapis, A.D., Sotiropoulou, P.A., Perez, S.A., Cacoullos, N.T., Papamichail, M., 2005. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol. Immunother.
4. Bouvier M., and Wiley D.C. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science (Washington, DC) 265 (1994) 398-402
5. Collins E.J., and Frelinger J.A. Altered peptide ligand design: altering immune responses to class I MHC/peptide complexes. Immunol. Rev. 163 (1998) 151-160
6. Disis M.L., Grabstein K.H., Sleath P.R., and Cheever M.A. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5 (1999) 1289-1297
7. Fremont D.H., Stura E.A., Matsumura M., Peterson P.A., and Wilson I.A. Crystal structure of an H-2K-b-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 2479-2483
8. Hogan K.T., Shimojo N., Walk S.F., Engelhard V.H., Maloy W.L., Coligan J.E., and Biddison W.E. Mutations in the alpha 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide. J. Exp. Med. 168 (1988) 725-736
9. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., Muramatsu S., and Steinman R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176 (1992) 1693-1702
10. Kuhns J.J., Batalia M.A., Yan S., and Collins E.J. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. J. Biol. Chem. 274 (1999) 36422-36427
11. Leggatt G.R., Hosmalin A., Pendleton C.D., Kumar A., Hoffman S., and Berzofsky J.A. The importance of pairwise interactions between peptide residues in the delineation of TCR specificity. J. Immunol. 161 (1998) 4728-4735
12. Madden D.R., Garboczi D.N., and Wiley D.C. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 75 (1993) 693-708
13. Meng W.S., and Butterfield L.H. Rational design of peptide-based tumor vaccines. Pharm. Res. 19 (2002) 926-932
14. Meng W.S., Butterfield L.H., Ribas A., Dissette V.B., Heller J.B., Miranda G.A., Glaspy J.A., McBride W.H., and Economou J.S. Alpha-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res. 61 (2001) 8782-8786
15. Meng W.S., Butterfield L.H., Ribas A., Heller J.B., Dissette V.B., Glaspy J.A., McBride W.H., and Economou J.S. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T-cell epitope derived from human alpha-fetoprotein. Mol. Immunol. 37 (2000) 943-950
16. Meng W.S., Von Grafenstein H., and Haworth I.S. A model of water structure inside the HLA-A2 peptide binding groove. Int. Immunol. 9 (1997) 1339-1346
17. Meng W.S., von Grafenstein H., and Haworth I.S. Water dynamics at the binding interface of four different HLA-A2-peptide complexes. Int. Immunol. 12 (2000) 949-957
18. Parker K.C., Bednarek M.A., and Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152 (1994) 163-175
19. Parker K.C., DiBrino M., Hull L., and Coligan J.E. The beta 2-microglobulin dissociation rate is an accurate measure of the stability of MHC class I heterotrimers and depends on which peptide is bound. J. Immunol. 149 (1992) 1896-1904
20. Parkhurst M.R., Salgaller M.L., Southwood S., Robbins P.F., Sette A., Rosenberg S.A., and Kawakami Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157 (1996) 2539-2548
21. Pearlman, D.A., Case, D.A., Caldwell, J.C., Seibel, G.L., Singh, U.C., Weiner, P., Kollman, P.A., 1991. AMBER.
22. Peiper M., Goedegebuure P.S., Izbicki J.R., and Eberlein T.J. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu. Anticancer Res. 19 (1999) 2471-2475
23. Peiper M., Goedegebuure P.S., Linehan D.C., Ganguly E., Douville C.C., and Eberlein T.J. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur. J. Immunol. 27 (1997) 1115-1123
24. Peoples G.E., Goedegebuure P.S., Smith R., Linehan D.C., Yoshino I., and Eberlein T.J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 432-436
25. Ribas A., Butterfield L.H., McBride W.H., Jilani S.M., Bui L.A., Vollmer C.M., Lau R., Dissette V.B., Hu B., Chen A.Y., Glaspy J.A., and Economou J.S. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 57 (1997) 2865-2869
26. Rognan D., Scapozza L., Folkers G., and Daser A. Molecular dynamics simulation of MHC-peptide complexes as a tool for predicting potential T-cell epitopes. Biochemistry 33 (1994) 11476-11485
27. Rongcun Y., Salazar-Onfray F., Charo J., Malmberg K.J., Evrin K., Maes H., Kono K., Hising C., Petersson M., Larsson O., Lan L., Appella E., Sette A., Celis E., and Kiessling R. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J. Immunol. 163 (1999) 1037-1044
28. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., Restifo N.P., Dudley M.E., Schwarz S.L., Spiess P.J., Wunderlich J.R., Parkhurst M.R., Kawakami Y., Seipp C.A., Einhorn J.H., and White D.E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4 (1998) 321-327
29. Ruppert J., Sidney J., Celis E., Kubo R.T., Grey H.M., and Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74 (1993) 929-937
30. Salter R.D., and Cresswell P. Impaired assembly and transport of HLA-A and -B antigens in a mutant T × B cell hybrid. EMBO J. 5 (1986) 943-949
31. Sette A., Vitiello A., Reherman B., Fowler P., Nayersina R., Kast W.M., Melief C.J., Oseroff C., Yuan L., Ruppert J., et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T-cell epitopes. J. Immunol. 153 (1994) 5586-5592
32. Sette A., Vitiello A., Reherman B., Fowler P., Nayersina R., Kast W.M., Melief C.J.M., Oseroff C., Yuan L., Ruppert J., Sidney J., Del Guercio M.-F., Southwood S., Kubo R.T., Chestnut R.W., Grey H.M., and Chisari F.V. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T-cell epitopes. J. Immunol. 153 (1994) 5586-5592
33. Sharma A.K., Kuhns J.J., Yan S., Friedline R.H., Long B., Tisch R., and Collins E.J. Class I major histocompatibility complex anchor substitutions alter the conformation of T-cell receptor contacts. J. Biol. Chem. 276 (2001) 21443-21449
34. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
35. Smith K.J., Reid S.W., Harlos K., McMichael A.J., Stuart D.I., Bell J.I., and Jones E.Y. Bound water structure and polymorphic amino acids act together to allow the binding of different peptides to MHC class I HLA-B53. Immunity 4 (1996) 215-228
36. Storkus W.J., Zeh H.J.d., Salter R.D., and Lotze M.T. Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution. J. Immunother. 14 (1993) 94-103
37. Stuber G., Leder G.H., Storkus W.T., Lotze M.T., Modrow S., Szekely L., Wolf H., Klein E., Karre K., and Klein G. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur. J. Immunol. 24 (1994) 765-768
38. Teng J.M., and Hogan K.T. Both major and minor peptide-binding pockets in HLA-A2 influence the presentation of influenza virus matrix peptide to cytotoixc T lymphocytes. Mol. Immunol. 31 (1994) 459-470
39. Townsend A., Ohlen C., Bastin J., Ljunggren H.G., Foster L., and Karre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides [see comments]. Nature 340 (1989) 443-448
40. van der Burg S.H., Visseren M.J., Brandt R.M., Kast W.M., and Melief C.J. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156 (1996) 3308-3314
41. Vitiello A., Marchesini D., Furze J., Sherman L.A., and Chesnut R.W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173 (1991) 1007-1015
42. Wentworth P.A., Vitiello A., Sidney J., Keogh E., Chestnut R.W., Grey H., and Sette A. Differences and similarities in the A2.1-restricted cytotoxic T-cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. 26 (1996) 97-101
43. Yoshino I., Goedegebuure P.S., Peoples G.E., Parikh A.S., DiMaio J.M., Lyerly H.K., Gazdar A.F., and Eberlein T.J. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res. 54 (1994) 3387-3390
44. Zweerink H.J., Gammon M.C., Utz U., Sauma S.Y., Harrer T., Hawkins J.C., Johnson R.P., Sirotina A., Hermes J.D., Walker B.D., et al. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J. Immunol. 150 (1993) 1763-1771